MicroRNA-155 Tissue Expression in Patients with Breast Cancer at Dr Haji Adam Malik Hospital, Medan

Henny Erina Saurmauli Ompusunggu1, Juwita2, Donny Nauphar3, Sumondang M. Pardede4, Hadyanto Lim5, Yahwardiah Siregar5,7

1) Department of Cellular and Molecular Biology, Faculty of Medicine, HKBP Nommensen University, Medan
2) Department of Biochemistry, Faculty of Medicine, Syiah Kuala University, Banda Aceh
3) Department of Biochemistry, Faculty of Medicine, Swadaya Gunung Jati University, Cirebon
4) Department of Pathology, Dr. H. Adam Malik Hospital, Medan
5) Master of Biomedical, Faculty of Medicine, North Sumatera University, Medan
6) Department of Pharmacology of the Faculty of Medicine, Methodist Indonesia University, Medan
7) Department of Biochemistry, Faculty of Medicine, North Sumatera University, Medan

ABSTRACT

Background: MicroRNA (miRNA) is non-coding RNA that comprises 18-22 nucleotides. miRNA binds its gene targets in the 3’-untranslated region (3’-UTR), causing direct degradation of mRNA and repressed translation of RNA. MicroRNA regulates various biological processes, including cell proliferation, apoptosis, cell growth, cell differentiation, and metabolism. Various changes have been identified in miRNA expression in different types of cancers. This study aimed to describe the expression of miR-155 in patients with breast cancer tissue in Haji Adam Malik Hospital in Medan.

Subjects and Method: This was a descriptive study. A total sample was 64 paraffin tissue blocks taken from female patients with breast cancer at the surgical oncology unit, Haji Adam Malik Hospital in 2013-2014. RNA sample were isolated and checked using a spectrophotometer followed by cDNA synthesis. Then this sample was analyzed for miR-155 expression by using Real Time qPCR. Histopathological grade data were obtained from the medical record.

Results: The miR-155 expression in the breast cancer patients is higher than that in the UniSp6 RNA Spike-in (internal controls). miR-155 expression was 29.64, 28.44, 29.22, in grade-I, grade-II, grade-III breast cancer, respectively. UniSp6 RNA Spike-in was 22.30, 22.89, 23.10, respectively in the control groups. Thus, increase in miR-155 expression was the highest in grade I breast cancer patients.

Conclusion: Increased miR-155 expression can be used as a biomarker for early diagnosis and prognosis of breast cancer.

Keywords: miRNA, miR-155, breast cancer.

Correspondence:
Henny Erina Saurmauli Ompusunggu. Department of Cellular and Molecular Biology, Faculty of Medicine, HKBP Nommensen University, Medan. Email: ompusunggu.henny@gmail.com

BACKGROUND

Cancer is the third leading cause of death worldwide after cardiovascular diseases and infections (Hauptman and Glavac, 2013). Breast cancer is the second highest incidence in women worldwide having ovarian cancer and about 7%-10% of all malignant tumors. It is estimated that worldwide more than 508,000 women die in 2011 from breast cancer, because most women with breast cancer diagnosed at advanced stages of the disease because early symptoms are not typical (WHO, 2013; Zhao et al., 2012).

Screening for breast cancer allows early diagnosis and potentially reduce mortality. Currently palpation is a tool most reliable screening for breast cancer (Zhao et
al., 2012). Although today much research done right look for biomarkers as a diagnostic tool and prognostic cancer, but still have not found an effective early detection techniques in order to reduce the number of deaths due to cancer (Hauptman and Glavac, 2013).

Grade histopathology, consisting of grade I, II, and III, the morphological assessment of the degree of differentiation of cancer tissue, which can be used to provide diagnostic and prognostic information in breast cancer (Tavassoli and Devilee, 2003; Dağlar et al., 2010). Histopathological examination method is a method of diagnosing breast cancer terpercayadalam of breast lesions, but it depends on how the sampling and readability of the results by an expert pathology (Oakley and going, 1995). Therefore, the validity of test results is still subjective. Therefore, it required continuous efforts to obtain more objective biomarker, sensitive and specific. One potential candidate cancer biomarkers in the future that has been researched lately is a miRNA.

Micro RNA are non coding-RNA that consists of about 18-22 nucleotides, which is transcribed from the intergenic regions of the genome and the genie who is a new gene regulator (Rodriguez et al., 2004). MicroRNA bind its gene targets in the 3’-untranslated region (3’- UTR), causing direct mRNA degradation or translational repression of mRNA (Valencia-Sanchez et al., 2006; Huntzinger and Izaurralde, 2011). MicroRNA is very stable, the tissue samples were preserved, even several years after formaline fixation and embedded in paraffin, and efficiently extracted from the specimen and is measured in (Lu et al., 2012; Szafranska et al., 2008).

MicroRNA has been implicated in the regulation of a wide spectrum of biological processes, including cell proliferation, apoptosis, growth, differentiation and metabolism. Various changes have been identified miRNA expression in different types of human cancer. In 2005, miRNA expression levels in 76 primary breast cancer tissues and 10 normal tissues using microarray analysis. They found changes in the regulation of miR-10b, miR-125b, miR-145, miR-21 and miR-155 are the most significant.

The cancer tissue studies conducted by Volinia (2006) using significance analysis of microarrays (SAM) and predictive analysis of microarrays (PAM) were obtained from six different types of solid tumor miR-21 and miR-155 as a top onkomiR (miRNA as a biomarker of poor prognosis). From the many miRNA are experiencing a change of regulation in breast cancer, the researchers chose miR-155 because it is based on the results research Mar-Aguilar (2013), proved that the expression of miR-145 and miR-155 are the most sensitive and specific for breast cancer. From the results of the study found the diagnostic test efficiency were 85.7% for miR-10b, miR-89.3% for 21, 89% for miR-125b, miR-96.4% for 145, 96% for miR -155,78% for miR-191.

The research question of this study: what is the miR-155 expression in grade-I, grade-II, grade-III breast cancer, in comparison with the control group (UniSp6 RNA Spike-in)?

SUBJECTS AND METHOD
This was a descriptive study. Samples were 64 paraffin blocks of female patients with breast cancer tissue in surgical oncology at Adam Malik Hospital in 2013-2014. It was taken from the bank block Anatomical Pathology Laboratory of Dr H. Adam Malik who met the inclusion criteria and obtained by purposive sampling.
Samples were first sliced paraffin blocks as much as 2-4 slices, and then to isolate total RNA, then check the quality and quantity of the isolated RNA using a NanoDrop spectrophotometer. CDNA synthesis is then performed using RT-PCR. Quantification analysis of miR-155 used Real Time qPCR to get value ExiLent Cq using SYBR Green master mix, primer sets of miR-155 (HSA-miR-155-5p), spike un-controlled primer set (UniSp6 RNA spike-ins). This study was approved by the Health Research Ethics Committee of the Faculty of Medicine University of North Sumatra.

RESULTS

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
</tr>
<tr>
<td>30-49</td>
<td>36</td>
</tr>
<tr>
<td>50-78</td>
<td>28</td>
</tr>
<tr>
<td>Histopathology Grade</td>
<td></td>
</tr>
<tr>
<td>Grade I</td>
<td>15</td>
</tr>
<tr>
<td>Grade II</td>
<td>38</td>
</tr>
<tr>
<td>Grade III</td>
<td>11</td>
</tr>
</tbody>
</table>

Characteristics of research subjects are presented in Table 1, whereas the expression of miR-155 image with UniSp6 RNA Spike-in (as internal control) in breast cancer tissue (value cq) is presented in Figure 1.

In this study, most patients are aged ≤ 49 years and is in line with research Wang (2010) which is the subject of research they are also more aged <48 years. Breast cancer affects more and more by young women, this is one of them caused by mutations in the genes BRCA1 and BRCA2 that increases the incidence of breast cancer is familial approximately 45% and of the familial.

The incidence of breast cancer in early-onset increased by approximately 80% (Mattiske et al., 2012; Miki et al., 1994). In addition, the menstrual ages ranging from early (<13 years) and/or experienced menopause older (≥55 years) had a higher risk of developing breast cancer (Kumar et al., 2007; Department of Health Affairs, 2009). The increased risk caused by the longer lifetime exposure to the hormones estrogen and progesterone (Tryggyadottir et al., 2003; Wrensch et al., 2003; Ostad and Parsa, 2011). Hormon estrogen and progesterone can trigger the proliferation of breast epithelial cells to become cancerous (Anderson, 2002)

Wang et al., (2010) and Lu et al., (2012), states the dominant subject of their study on grade II and III. Most women with breast cancer diagnosed at advanced stages of the disease because early symptoms are not typical (Zhao et al., 2012).

Based on Figure 1, we can see the results of the paraffin blocks of breast tissue of women with breast cancer found an increased expression of miR-155 in all of the study subjects either grade I, grade II and grade III compared with UniSp6 internal controls.
DISCUSSION

The results of this study are consistent with those of Lu (2012). Lu’s study identifies miR-155 expression using the Real Time qPCR. In the Lu study, miR-155 expression was 5-6 times higher in breast cancer than that in normal breast tissue, and it was statistically significant (p < 0.05).

Likewise, the miR-155 expression was 5-6 times higher in the plasma of breast cancer than that in normal female plasma, and it was statistically significant (p < 0.05).

This finding is also consistent with that of one Wang (2010). In Wang’s study, the miR-155 expression was higher in both tissue sample and blood sample in patients with benign breast tumors, grade II, and grade III breast cancer patients, than that of normal controls, and it was statistically significant (p < 0.05).
From the study it was also found a strong correlation (r=0.85) between the miR-155 expression in tissue and serum.

In another study conducted by Mar-Aguilar (2013), it was also found that the miR-155 expression in the serum of breast cancer patients was significantly higher than the miR-155 expression in the serum of normal women, and it was statistically significant (p < 0.001).

This study also found that miR-155 expression had high sensitivity (94.40%) and high specificity (100%) when compared with the gold standard histopathology assessment. This means that the false negative rate is very low, while the false positive rate is zero. The efficiency of miR-155 expression as diagnostic test was high (96.4%).

This findings further reaffirm that the miR-155 expression in serum reflects the condition of the miR-155 expression in the network. Further, this findings confirm that the examination of serum miR-155 as a diagnostic method is minimally invasive and accurate.

These results support the miR-155 expression as a potential biomarker for early detection, early diagnosis, and prognosis of breast cancer. But further studies are needed to provide more evidence.

This study found that the miR-155 expression on the whole network of breast cancer patients is higher than that of UniSp6 RNA Spike-in (i.e. internal controls). In particular, the miR-155 expression were highest in grade I breast cancer patients.

The researchers of the current study suggest that further studies be conducted to compare the miR-155 expression in tissues and serum of patients with benign breast tumor, grade I, II, and III breast cancer, and with different histopathological types (ductal and lobular types).

Research in miR-155 expression can be used to develop an accurate and less invasive peripheral blood-based biomarker for the detection, early diagnosis, and prognosis of breast cancer metastasis.

**REFERENCE**


Lu Z, Ye Y, Jiao D, Qiao J, Cui S, Liu Z (2012). miR-155 and miR-31 are diffe-
Differentially Expressed in Breast Cancer Patients and are correlated with the estrogen receptor and progesterone receptor status. Oncology Letters, 4: 1027-1032.


